SCHEMBL3147282

SCHEMBL3147282

C=CCC1[CH]C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19127826 0.77
SCHEMBL17239401 0.75 ALDH1A1 (0.36)
SCHEMBL17239398 0.75 ALDH1A1 (0.31)
SCHEMBL17239400 0.75 ALDH1A1 (0.36)
SCHEMBL17239399 0.75 ALDH1A1 (0.31)
SCHEMBL16288842 0.73
SCHEMBL1081400 0.71
SCHEMBL2162558 0.71
SCHEMBL2160980 0.69
SCHEMBL9444567 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6475473-B1 Perfume compositions QUEST INTERNATIONAL B.V. (NL) 2002-11-05 US claimed
CN-116813596-A Macrocyclic HCV NS3 inhibits tripeptide synthesis 吉利德科学公司 2023-09-29 CN disclosed
US-11718619-B2 Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators ARDELYX, INC. (US) 2023-08-08 US disclosed
CN-111320610-B Macrocyclic HCV NS3 inhibits tripeptide synthesis 吉利德科学公司 2023-06-06 CN disclosed
US-20230139597-A1 HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS ARDELYX, INC. (US) 2023-05-04 US disclosed
CN-115974883-A Method for synthesizing chiral seven-membered ring bridged 3, 4-fused tricyclic indole 河南师范大学 2023-04-18 CN disclosed
CN-109970629-B Process for preparing antifungal compounds 迈科维亚医药公司 2023-04-11 CN disclosed
EP-3954684-A1 PROCESS FOR THE PREPARATION OF HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS Ardelyx, Inc. (US) 2022-02-16 EP disclosed
US-20210300927-A1 ISOXAZOLYL-CARBONYLOXY AZABICYCLO[3.2.1]OCTANYL COMPOUNDS AS FXR ACTIVATORS ARDELYX, INC. (US) 2021-09-30 US disclosed
US-11091482-B2 Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators ARDELYX, INC. (US) 2021-08-17 US disclosed
WO-2005094514-A2 HETEROARYL PIPERIDINE GLYCINE TRANSPORTER INHIBITORS MERCK & CO., INC. (US) 2005-10-13 WO disclosed
US-6846802-B2 Macrocyclic NS3-serine protease inhibitors of hepatitis C virus comprising N-cyclic P2 moieties SCHERING CORPORATION (US) 2005-01-25 US disclosed
EP-1268525-A2 MACROCYCLIC NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS COMPRISING N-CYCLIC P2 MOIETIES SCHERING CORPORATION (US) 2003-01-02 EP disclosed
US-20020107181-A1 Macrocyclic NS3-serine protease inhibitors of hepatitis C virus comprising N-cyclic P2 moieties SCHERING CORPORATION 2002-08-08 US disclosed
WO-2001077113-A2 MACROCYCLIC NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS COMPRISING N-CYCLIC P2 MOIETIES SCHERING CORPORATION (US) 2001-10-18 WO disclosed
WO-2001064216-A1 4-ALKYL PIPERIDINYL PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY MERCK & CO., INC. (US) 2001-09-07 WO disclosed
EP-0912175-A4 FIBRINOGEN RECEPTOR ANTAGONISTS MERCK & CO INC (US) 1999-09-08 EP disclosed
EP-0912175-A1 FIBRINOGEN RECEPTOR ANTAGONISTS Merck & Co., Inc. (US) 1999-05-06 EP disclosed
WO-1998000134-A1 FIBRINOGEN RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 1998-01-08 WO disclosed
US-4939020-A Core member for fabrication of shaped plastic Toyo Coth Co., Ltd. (JP) 1990-07-03 US disclosed